OptiNose, Inc.

OptiNose, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. OptiNose, Inc. is not a good growth stock. OptiNose, Inc. is not very popular among insiders. OptiNose, Inc. is a good stock to invest in, but there are better stocks to choose.
Log in to see more information.
OptiNose, Inc. is a pharmaceutical company, which engages in the development and commercialization o...
OPTN Fundamental Data by TradingView

News

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

Globe Newswire YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...\n more…

Even after rising 12% this past week, OptiNose (NASDAQ:OPTN) shareholders are still down 85% over the past five years
Even after rising 12% this past week, OptiNose (NASDAQ:OPTN) shareholders are still down 85% over the past five years

Simply Wall St Research OptiNose's (Nasdaq:OPTN) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.\n more…

OptiNose, Inc. (NASDAQ:OPTN) Stock Position Lowered by Assenagon Asset Management S.A.
OptiNose, Inc. (NASDAQ:OPTN) Stock Position Lowered by Assenagon Asset Management S.A.

Ticker Report Assenagon Asset Management S.A. lowered its position in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 12.5% in the 2nd quarter, according to its most recent disclosure with the Securities...\n more…

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...\n more…

Head-To-Head Analysis: OptiNose (NASDAQ:OPTN) versus ProQR Therapeutics (NASDAQ:PRQR)
Head-To-Head Analysis: OptiNose (NASDAQ:OPTN) versus ProQR Therapeutics (NASDAQ:PRQR)

Zolmax OptiNose (NASDAQ:OPTN - Get Free Report) and ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two...\n more…

Vanguard Group Inc. Increases Position in OptiNose, Inc. (NASDAQ:OPTN)
Vanguard Group Inc. Increases Position in OptiNose, Inc. (NASDAQ:OPTN)

Ticker Report Vanguard Group Inc. increased its holdings in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 1.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission...\n more…